Surfers Roger Green, Jörn Schattenberg and Louise Campbell embark on their first exclusive discussion together in a while without any guest panelists. After several weeks of attending and reviewing conferences, the trio take the opportunity to talk about what the next year holds for the NAFLD-metabolic disease link.
Program speakers Mazen Noureddin, Sven Francque and Hannes Hagström join Roger Green, on-site from Dublin to review their thoughts and key takeaways immediately after the NAFLD Summit ended. In this final conversation, the group discusses NITs and what will change between now and when this conference convenes next year.
Program speakers Mazen Noureddin, Sven Francque and Hannes Hagström join Roger Green, on-site from Dublin to review their thoughts and key takeaways immediately after the NAFLD Summit ended. In this conversation, the group discusses the impact of weight change and lifestyle modification in clinical trials.
Program speakers Mazen Noureddin, Sven Francque and Hannes Hagström join Surfer, Roger Green, on-site from Dublin to review their thoughts and key takeaways immediately after the NAFLD Summit ended. In this conversation, the group explores issues around clinical trial design, focusing specifically on the value of Phases 2a and 2b and whether improvement in patient self-management during trials is a research artifact or a replication of reality.
Program speakers Mazen Noureddin, Sven Francque and Hannes Hagström join Surfer, Roger Green, on site from Dublin to review their thoughts and key takeaways immediately after the NAFLD Summit ended. In this conversation, the group contextualizes and compares the NAFLD Summit to other major liver conferences and meetings. The group also assesses Session 9 from Friday, a series of case studies on why trials fail.
Program speakers Mazen Noureddin, Sven Francque and Hannes Hagström join Surfer, Roger Green, on site from Dublin to review their thoughts and key takeaways immediately after the NAFLD Summit ended. In this conversation, the group discusses underreported alcohol use in clinical trials and the impact of treating comorbidities on the treatment of NAFLD.
The 2022 NAFLD Summit proved to be an in-depth, successful conference brought to life by key opinion leaders in fatty liver and metabolic disease from around the world. In Season 3, Episode 46, Surfer Roger Green hosts a review on site in Dublin with presenting speakers Mazen Noureddin, Sven Francque and Hannes Hagström.
In this conversation From Inside the Vault, NAIL-NIT co-leads Stephen Harrison and Mazen Noureddin and retrospective analysis co-leads Naim Alkhouri and Jörn Schattenberg join Louise Campbell and Roger Green to discuss designs and plans for NAIL-NIT retrospective analysis.
In a review of Paris NASH 2022, Surfers Roger Green, Louise Campbell, and Jörn Schattenberg are joined by patient advocate, Jeff McIntyre. In this conversation, the group discusses presentations on adaptive trial strategies, trial recruitment and reducing screen fail rates, and the impact of educating patients on better self-care.
In a review of Paris NASH 2022, Surfers Roger Green, Louise Campbell, and Jörn Schattenberg are joined by patient advocate, Jeff McIntyre. In this conversation, the group discusses the opening and closing sessions, data collection and the rate of growth for cirrhosis, and Fatty Liver in the metabolic context.
Hepatologist Naim Alkhouri and Endocrinologist Scott Isaacs join Ken Cusi and Roger Green to discuss drug choices prescribers can make
